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Fenestrated endovascular aortic repair has been used with increasing frequency to treat complex aortic aneurysms. The
Zenith fenestrated stent graft system (Cook Medical Inc, Brisbane, Queensland, Australia) was approved for commercial
use in the United States in April 2012, offering a custom-made design with up to three fenestrations to treat short-neck
infrarenal and juxtarenal abdominal aortic aneurysms. This report and the Video presentation (online only) summarize
the preoperative planning, stent graft design, and technique of implantation of a Zenith fenestrated stent graft using
a totally percutaneous approach in an 80-year-old female patient with a 6-cm juxtarenal abdominal aortic aneurysm. The
patient was dismissed home the next day without complications, and a computed tomography angiography at 12 months
showed no endoleak or stent graft complications. (J Vasc Surg 2014;59:1456-61.)Fenestrated stent grafts have been increasingly used
to treat complex aortic aneurysms involving visceral
branches.1 These devices are designed with fenestrations
or scallops, or both, to incorporate segments of the visceral
arteries into the proximal sealing zone. The Zenith fenes-
trated stent graft system (Cook Medical Inc, Brisbane,
Queensland, Australia) was recently approved for commer-
cial use in the United States with indication in patients with
infrarenal aortic necks >4 mm and <15 mm in length. The
device design includes a scallop, a small or large fenestra-
tion, with a maximum of three fenestrations, two of the
same type (Fig 1). This article accompanies a Video presen-
tation (online only) and describes the technique of implan-
tation of the Zenith fenestrated stent graft to treat
juxtarenal abdominal aortic aneurysms (AAAs).
CASE PRESENTATION
An 80-year-old female patient presented with an
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6notable for hypertension, hyperlipidemia, and pulmonary
embolism. Computed tomography angiography (CTA)
with centerline of ﬂow was used to select a proximal
landing zone of >2 cm in the normal aorta and to design
a custom fenestrated stent graft with two small reinforced
fenestrations for the renal arteries and a scallop for the
superior mesenteric artery.
Design and planning. The stent graft design was based
on analysis of CTA with centerline of ﬂow measurements to
determine precise estimates of lengths, axial clock position,
arc lengths, and angles. Detailed description of design
planning has been reported elsewhere.2 A 20-mm proximal
landing zone was selected on healthy aortic anatomy, with
parallel walls, an outer-to-outer diameter of $19 and
#31mm, and no calcium or thrombus. Based on selection of
the landing zone, the fenestrated component was positioned
just below the superior mesenteric artery, and the device was
designed with two small fenestrations (6  6 mm) for both
renal arteries. A universal bifurcated component and iliac
limb extensions were also manufactured.
Technique. The procedure was performed under
general endotracheal anesthesia in a hybrid endovascular
suitewith a total percutaneous approach. Each femoral punc-
ture was preclosed using two Perclose devices (Abbott
Vascular, Abbott Park, Ill). The right femoral access was
used for target vessel catheterization and the left for introduc-
tion of the fenestrated and bifurcated components (Video,
online only). Technical details are summarized below:
Multi-sheath femoral access. A 20F Check-Flo
sheath (Cook Medical Inc, Bloomington, Ind) was
advanced over a 0.035-inch Lunderquist guidewire (Cook
Medical Inc) through the right femoral approach. The left
brachial approach is typically not needed for juxtarenal
Fig 1. A, Three-dimensional reconstruction of computed tomography angiography (CTA) demonstrates a juxtarenal
abdominal aortic aneurysm (AAA). B, The patient was treated using a Zenith fenestrated stent graft (Cook Medical
Inc), consisting of a fenestrated proximal component, a bifurcated distal component, and a contralateral iliac limb
extension. The fenestrated component is designed with one to three fenestrations, including scallop, small, and large
fenestrations. C, A follow-up CTA at 24 months shows a widely patent fenestrated stent graft with no endoleak.
Reproduced with permission of the Mayo Foundation for Medical Education and Research All rights reserved.
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right-handed operators, the branches and fenestrations are
accessed using the right femoral approach, whereas the
fenestrated and bifurcated components are introduced
through the left side. The sheath valve was punctured with
two 55-cm 7F sheaths for introduction of selective cathe-
ters (Fig 2, A). The patient was systemically heparinized to
achieve an activated clotting time >300 seconds.
Target vessel catheterization. Precatheterization of
the renal arteries was used to minimize contrast injection
during device deployment. Using 5F Kumpe catheters
(Cook Medical Inc) supported by 7F left interior mammary
artery guide catheters (Cordis Corp, Bridgewater, NJ), we
catheterized both renal arteries (Fig 2, B). Small-volume
hand injections (3 mL contrast in 7 mL saline) were used
to conﬁrm access into the renal arteries.
Device orientation and deployment. Themain fenes-
trated component was oriented extracorporeally by rotating
the anterior and posterior markers (Fig 2, C). The main
fenestrated stent graft componentwas introduced through the
left femoral approach and deployed with perfect apposition
between the fenestrations and the target catheters (Fig 3, A).
Target vessel catheterization and sheath advance-
ment. After deployment of the device, the selective cathe-
ters were sequentially removed from the renal arteries and
used to regain access to the main fenestrated component,
fenestration, and target vessel (Fig 3, B). After successful
renal catheterization, small-volume injections were used to
conﬁrm that the renal branch was of adequate diameter to
accept a 0.035-inch Rosen wire (Cook Medical Inc). Next,7F hydrophilic Ansel sheaths (Cook Medical Inc) with
ﬂexible dilators were advanced into the renal arteries
(Fig 3, C). Renal alignment stents were positioned into the
renal arteries under protection of the sheath.
Removal of diameter-reducing tie and deployment
of the top cap. The diameter-reducing tie was removed,
and the uncovered stent was deployed. The top cap was
retrieved before placement of the renal alignment stents to
prevent damage to the renal stents (Fig 4, A).
Proximal neck balloon dilatation. The proximal neck
was dilated using a Coda balloon (Cook Medical Inc)
before the renal alignment stents were placed (Fig 4, B).
Target vessel stenting. Position of the renal stents was
conﬁrmed by small-volume injection, followed by sequential
deployment of the renal alignment stents with 3 mm to
5 mm of stent protruding into the aortic lumen (Fig 4, C).
Each renal stent was ﬂared using a 10-mm  2-cm balloon
(Fig 4, D). Selective renal angiography was performed using
10-mL full-strength contrast, after administration of 100 mg
of nitroglycerin to minimize spasm. A low threshold to use
self-expandable stents overlapping the distal alignment stent
is recommended if there is kink on angiography.
Universal bifurcated component. Iliac angiography
using diluted contrast was performed through the sheath
to demonstrate the location of the iliac bifurcation. The
bifurcated component was advanced through the left
femoral approach, oriented, and deployed with preserva-
tion of the internal iliac artery. The dilator of the bifurcated
device often encroaches the contralateral renal stent, which
can be protected by leaving an inﬂated 10-mm balloon in
Fig 2. Right femoral access is obtained using a 20F Check-Flo sheath (Cook Medical Inc). A, The sheath valve is
punctured with two 7F sheaths for introduction of guide catheters and catheters, (B) which are used for selective
catheterization of the renal arteries. C, After the target vessels are located, the device is oriented extracorporeally using
the anterior and posterior radiopaque markers for orientation. Reproduced with permission of the Mayo Foundation
for Medical Education and Research All rights reserved.
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overlap of two stents is recommended between the bifur-
cated and fenestrated components.
Gate catheterization and contralateral iliac exten-
sion. The contralateral gate was catheterized using a
Glidewire (Terumo Medical Corp, Somerset NJ), which
was exchanged for a 0.035-inch Lunderquist guidewire
and a marker catheter (Fig 5, B). Limited iliac angiography
was performed through the sheath to conﬁrm location of
the iliac bifurcation, followed by deployment of the
contralateral limb extension (Fig 5, C).
Balloon dilatation of attachment sites and distal
landing zones. The attachment sites and distal landing
zoneswere dilatedwith aCodaballoon, followedby comple-
tion angiography, which conﬁrmed widely patent visceral
arteries, bifurcated fenestrated stent graft and iliac arteries,
with no endoleak (Fig 5, D).The total operative time was 110 minutes, ﬂuoroscopy
time was 40 minutes, and 62 mL of iodinated contrast was
administered. The patient was dismissed home on the
second postoperative day with no complications. CTA
obtained at dismissal and at 1, 6, and 12 months revealed
no endoleak, widely patent visceral branches, and decrease
in aneurysm diameter.
DISCUSSION
Fenestrated stent grafts allow incorporation of visceral
branches to treat pararenal and thoracoabdominal aortic
aneurysms using an endovascular approach.3 Current
evidence from single-center reports, multicenter registries,
and systematic reviews demonstrates that the technique is
reproducible, with high rates of technical success and low
morbidity (12%-16%) and mortality (2%-6%).1,4,5 Two
systematic reviews have shown that treatment of pararenal
Fig 3. A, The fenestrated component is introduced via the left femoral approach and deployed with the fenestrations
matching the target catheters. B, Each catheter and guide catheter is sequentially removed from the renal artery and
used to regain access into the fenestrated stent graft, fenestration, and renal artery. C, Seven French sheaths are
advanced to the renal arteries over 0.035-inch Rosen guidewires (Cook Medical Inc). Reproduced with permission of
the Mayo Foundation for Medical Education and Research All rights reserved.
Fig 4. A, After both renal sheaths are positioned, the diameter-reducing tie is removed, allowing deployment of the
top cap and device. B, The top cap is retrieved, and the proximal sealing stents are balloon dilated using a Coda balloon
(Cook Medical Inc). C, Sequential stenting is performed by deployment of the alignment iCast balloon-expandable
covered stents (Atrium Medical Corp, Hudson, NH) with 3-mm to 5-mm into the aortic lumen, (D) followed by
ﬂaring of the proximal portion of each stent using a 10-mm angioplasty balloon. Reproduced with permission of the
Mayo Foundation for Medical Education and Research All rights reserved.
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and renal dysfunction compared with open repair.6 In the
United States pivotal study, a preliminary report of the ﬁrst
30 patients demonstrated no deaths, type I and III endo-
leak, aneurysm rupture, migration, or conversion to open
repair.2 It is estimated that >6500 patients have been
treated worldwide by fenestrated stent grafts (personal
communication from Cook Medical Inc, April 2013).
Some technical aspects should be noted. The device
approved in the United States allows only a single-wide
(10-mm) scallop. In other countries, the device may beordered with double-wide or triple-wide scallops (20-
30 mm). Although scallops are traditionally designed
not to be stented, single-wide scallops can be associated
with life-threatening vessel thrombosis when not aligned
by a stent. Precatheterization is not an absolute require-
ment of the technique. However, we strongly recommend
precatheterization or use of on-lay CTA to minimize use
of contrast during deployment of the fenestrated compo-
nent and branch vessel access. These techniques allow
very precise deployment and vessel access with little
contrast use.
Fig 5. The universal bifurcated component is deployed after placement of the alignment stents. A, Note that the
dilator of the bifurcated component often encroaches the contralateral renal stent, which can be protected by the
balloon (inset). B, The bifurcated component is deployed with at least a two-stent overlap to minimize risk of
component separation. C, Access to the contralateral gate is established, followed by placement of the iliac limb
extension. D, Completion angiography demonstrates widely patent fenestrated stent graft with no endoleak.
Reproduced with permission of the Mayo Foundation for Medical Education and Research All rights reserved.
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4 to 6 weeks for device manufacturing, which limits their
utility in patients with excessively large, symptomatic, or
contained ruptured AAAs. Off-the-shelf designs are
currently under investigation, with estimates that >80% of
patients have suitable anatomy for these devices.7,8 The
Ventana Endologix (Endologix Inc, Irvine, Calif) design
applies the concept of movable fenestrations, with >85%
visceral artery incorporation.8 The p-Branch design (Cook
Medical Inc) uses pivot fenestrations with two possible
designs that incorporate the visceral arteries in 80% of
patients.7 The designs of these two devices have been previ-
ously described.7,8 Mendes et al9 recently reported the
anatomic feasibility of these two designs in 390 patients
treated for pararenal AAAs. In their study, only 42% and
49% of patients met liberal anatomic recommendations for
the Ventana and p-Branch design, indicating that additional
designs and a custom-made option are still needed.9
Fenestrated stent grafts have the potential to signiﬁcantly
decreasemortality andmorbidity comparedwith open repair.
Nonetheless, their use in low-risk patients should be carefully
analyzed, given that open repair can be performed with low
mortality in select centers.Oderichet al10 reportedamortality
of 1.1% in 465 patients treated for complex AAAs.
Critical issues that need to be considered include patency
of visceral branches, changes in renal function, endoleaks,
reinterventions, and prevention of aneurysm rupture.
Patency of fenestrated branches is>98% at 5 years.11 Factors
associated with loss of target vessels included unstentedfenestrations, small vessel diameter (<4 mm), target vessel
dissection or occlusive disease, inadequate device planning,
and stent graft migration.11 Permanent renal function dete-
rioration occurs in 4% to 8% of patients, which is comparable
with open repair. Rates of dialysis average 3% with fenes-
trated repair (range, 0%-5%). Endoleak from attachment sites
(types I and III) occur in <3% of patients.1,4,5 Rates of
secondary reinterventions are higher compared with open
repair, averaging 0% to 24%.6
CONCLUSIONS
This report summarizes the technique of implantation
of the Zenith fenestrated stent graft to treat juxtarenal
AAAs, emphasizing important technical aspects of the
procedure to minimize risk of complications.
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at www.jvascsurg.org.DISCUSSIONDr William D. Jordan Jr, (Birmingham, Ala). First, congrat-
ulations to Dr Oderich and the video production company at the
Mayo Clinic for this outstanding video. Also, thanks to the program
committee for askingme to open the discussion for this presentation.
The percutaneous technique of this fenestrated endograft was well
annotated in the video, and the results are quite remarkable.
A few questions for Gustavo: explain to us how this technique
is particularly different from that demonstrated to us earlier in this
meeting presented by the Southwestern group. What are you
doing that makes the operative time so short and the contrast
load rather low? The abstract reports 82 minutes of OR time
and 40 minutes of ﬂuoro. That’s half of the operative time related
to ﬂuoro time. Does this mean longer cases are taking similar
proportion of ﬂuoro time? So, a 3-hour case might use 90 min
of ﬂuoro, which seems rather excessive. What are the tricks to limit
ﬂuoro time to keep the patient and the operator safe?
Additionally, I have some questions related to the percuta-
neous technique. Recall that Dr Nelson has presented the results
of the PEVAR trial that showed reduced operative times with the
Proglide device in the Endologix trial. Contrast his report with
the January JVS manuscript from the Baylor team that showed an
equivalent learning curve and reduced operative times regardless
of the closure device used. Now, is your short operative time related
to your special technique, your prior closure experience, or the
proﬁciency with this endograft? While our group also performs
percutaneous technique for EVAR, I believe the complication
rate of percutaneous is quite similar to the wound infection rate
for a small cutdown to expose a short segment of the femoral artery.
Do you have similar opinion from the Mayo experience?
Finally, let me ask you to consider a different perspective: is
operative time an appropriate surrogate for quality? While we all
seek efﬁciency, too fast of an operation might be a problem.
Some are known to consider a longer operation a superior one,
but should we really always pursue speed as the best way?
Thank you again for bringing this presentation to our
meeting, and I thank the association for the privilege of the ﬂoor.
Dr Gustavo S. Oderich. Thank you for your comments. I will
try to remember all of them. First, starting with a comparison of the
technique using a manufactured ZFEN device with the one presented
by the UT Southwestern group and Carlos Timaran, Dr Timaran’s
technique involves the use of a modiﬁed stent graft and as such, it is
done with cannulation of the target vessels coming via the brachial
artery, often with preloaded wires. That is distinctly different from
the commercially approved device, which is intended to be done
from the transfemoral approach. It is actually critical to do from the
femoral approach, because the device has a top cap and is constrained
by a diameter reducing tie; so once you remove the diameter reducing
wire, you are committed to the device being in a certain position, and
by using the diameter reducing tie and the top cap, not only can you
advance your sheaths easier to the target vessels, but it is a saferprocedure with less risk of vessel loss. We also have used a similar tech-
nique as presented by Carlos and his group. Our preference is to do at
least the celiac and SMA coming from the brachial artery and the renal
arteries coming from the transfemoral approach.
Letme just tell youa littlebitmoreon thepercutaneous technique.
I think that it is similar to what has been presented by the UT South-
western group at the SVS meeting a few years ago. We use ultrasound
guidance and amicropuncture set. Our preference has been to use two
Perclose devices for each puncture, instead of the Prostar device.
I can tell you that on average a fenestrated repair with two to three
fenestrations is consistently donewith a total operating timeunder 2 to
3 hours. I would say that the average ﬂuoroscopy time of this case is
similar to what has been reported in the trial, which was under 50
minutes. It is a good comment that usually the operative time tends
to be 3 times the ﬂuoroscopy time, but I cannot explain why this
was not the case in this patient, except for the fact the casewas straight
forward.Typicallywith thepercutaneous cases, however, particularly if
it is done by someone who has already overcome the learning curve,
there is very little time beyond just the ﬂuoroscopy itself. There are
several tips to limit ﬂuoroscopy. First, I think with complex cases the
most experienced person has to be running the ﬂuoroscopy pedal to
avoid unnecessary exposure to radiations. If you have someone assist-
ing during the case, there are certainly portions of the case that can be
done simultaneously, like cannulation of both renal arteries by two
different operators, or one working form the arm and the other one
working from the femoral approach at the same time.
The other critical technical point with this case is really to limit
contrastuse and this is something that Ihave learned toavoid, including
predeployment angiographies.We rely totally on ourmeasurements by
the CT to select the fenestrated part, the bifurcated part, and the iliac
limbs and trust those measurements. We use diluted contrast, which
is typically done with small hand injection of 3 mL of contrast in 7
mL of saline. For power injections, 50/50 contrast is used. And, typi-
cally a case that goes uneventfulwithout endoleakor additionalmaneu-
vers tends to be less than 80 mL for total amount of contrast.
I do not know if I addressed all of the comments. I agree that
speed is certainly not the main goal. I think that main goal is to do it
safely, and to limit unnecessary manipulations, be precise in a step-
wise safe fashion, to keep an eye on the tip of your wire because
perforations of renal arteries and branches are certainly one of the
most dreaded problems with a fenestrated repair; attention to detail.
I have to say that in these cases you can get distracted because there
are so many steps. One complication that has happened to me and I
think has happened to Roy Greenberg and others, and illustrates
how important it is to pay attention to detail, is the failure to cannu-
late the gate and end up placing the ﬁnal iliac limb outside of the
gate. Sometimes the wire can go between the fenestrated and bifur-
cated component, creating the impression you are in the right place.
It is critical to pay attention to detail rather than paying attention to
the clock or trying to do a fast operation.
